Astria Therapeutics (NASDAQ:ATXS) Trading 10.2% Higher

Astria Therapeutics, Inc. (NASDAQ:ATXS) shares traded up 10.2% during trading on Thursday . The stock traded as high as $11.00 and last traded at $11.00. 195,701 shares traded hands during trading, a decline of 73% from the average session volume of 737,700 shares. The stock had previously closed at $9.98.

Analyst Upgrades and Downgrades

ATXS has been the topic of several research analyst reports. HC Wainwright restated a “buy” rating and set a $16.00 target price on shares of Astria Therapeutics in a research note on Tuesday. Evercore ISI upgraded Astria Therapeutics to a “strong-buy” rating in a research note on Wednesday. Wedbush reiterated an “outperform” rating and issued a $22.00 target price on shares of Astria Therapeutics in a research note on Tuesday. Oppenheimer upped their price target on shares of Astria Therapeutics from $25.00 to $26.00 and gave the company an “outperform” rating in a research note on Tuesday. Finally, TD Cowen began coverage on shares of Astria Therapeutics in a research note on Monday, July 29th. They set a “buy” rating and a $35.00 price objective for the company. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $25.20.

Astria Therapeutics Trading Up 1.0 %

The firm has a market capitalization of $613.93 million, a PE ratio of -4.82 and a beta of 0.73. The firm’s fifty day moving average price is $10.17 and its 200 day moving average price is $11.36.

Astria Therapeutics (NASDAQ:ATXS) last announced its quarterly earnings results on Monday, August 12th. The biotechnology company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.05). On average, analysts predict that Astria Therapeutics, Inc. will post -1.62 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of ATXS. AJOVista LLC purchased a new position in shares of Astria Therapeutics during the 4th quarter valued at approximately $51,000. Vivo Capital LLC grew its position in shares of Astria Therapeutics by 47.7% during the 4th quarter. Vivo Capital LLC now owns 2,482,727 shares of the biotechnology company’s stock valued at $19,067,000 after acquiring an additional 801,528 shares during the period. Panagora Asset Management Inc. purchased a new position in shares of Astria Therapeutics in the 4th quarter valued at about $119,000. Trexquant Investment LP purchased a new position in Astria Therapeutics during the fourth quarter worth approximately $409,000. Finally, Affinity Asset Advisors LLC grew its holdings in Astria Therapeutics by 46.6% in the fourth quarter. Affinity Asset Advisors LLC now owns 1,466,465 shares of the biotechnology company’s stock valued at $11,262,000 after purchasing an additional 466,165 shares during the period. 98.98% of the stock is owned by institutional investors and hedge funds.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.